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ABSTRACT
Under physiological conditions, PD-1/PD-L1 interactions regulate unwanted over-reactions of immune
cells and contribute to maintain peripheral tolerance. However, in tumor microenvironment, this inter-
action may greatly compromise the immune-mediated anti-tumor activity. PD-1+ NK cells have been
detected in high percentage in peripheral blood and ascitic fluid of ovarian carcinoma patients. To
acquire information on PD-1 expression and physiology in human NK cells, we analyzed whether PD-1
mRNA and protein are present in resting, surface PD-1−, NK cells from healthy donors. Both different
splicing isoforms of PD-1 mRNA and a cytoplasmic pool of PD-1 protein were detected. Similar results
were obtained also from both in vitro-activated and tumor-associated NK cells. PD-1 mRNA and protein
were higher in CD56dim than in CD56bright NK cells. Confocal microscopy analyses revealed that PD-1
protein is present in virtually all NK cells analyzed. The present findings are compatible with a rapid
surface expression of PD-1 in NK cells in response to appropriate, still undefined, stimuli.
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Introduction
NK cells play a major role in innate defenses against
viruses and tumors.1,2 In humans, NK cells can be distin-
guished in two phenotypically and functionally distinct
subsets on the basis of CD56 expression levels.3 While
CD56dim cells are mainly cytotoxic and are largely preva-
lent in peripheral blood (PB), CD56bright NK cells display
immunoregulatory activity, produce pro-inflammatory
cytokines (IFN-γ and TNFα), and are prevalent in tissues
and secondary lymphoid organs.4 NK cell function is
regulated by an array of surface receptors with activating
or inhibitory activity. Natural Cytotoxic Receptors
(NCRs), represented by NKp30, NKp44 and NKp46, are
some major activating receptors allowing tumor cell
recognition and killing.5 Other activating receptors, able
to trigger NK cell-mediated killing of tumor cells, are
NKG2D and the co-activating receptor/adhesion molecule
DNAM-1.6 Important inhibitory receptors, such as KIRs,
CD94/NKG2A and LIR-1, regulate NK cell function
through the recognition of the classical and non-classical
Human Leukocyte Antigen (HLA) class I molecules.7
In recent years, major molecular checkpoints have been
shown to control/inactivate different immune cell types, main-
tain peripheral tolerance and finely regulate the overall immune
response. Among these checkpoints, Programmed Cell Death
(PD-1) may be expressed on activated T cells regulating their
proliferation and antigen-specific responses upon interaction
with the PD-ligands 1 (PD-L1) and 2 (PD-L2) expressed by
antigen-presenting cells (APC).8-11 However, when PD-L1/PD-
L2 are expressed on tumor cells, T cell-mediated anti-tumor
activity may be severely compromised.12,13 Recently, PD-1 has
been detected in variable proportions also in a subset of fully
mature NK cells (CD56dimNKG2A−KIR+CD57+) isolated from
some Cytomegalovirus (CMV)-seropositive healthy donors
(HDs). In addition, PD-1 was found to be expressed in NK
cells derived from a fraction of peripheral blood and, at higher
frequency, in ascites of patients with ovarian carcinoma.14
Notably, in all cases, CD56bright cells were consistently negative
for PD-1 surface expression. The expression of PD-1 in NK
cells is particularly relevant in case of tumors that have lost or
down-regulated HLA-I molecules. While these tumors escape
T cell control, they become potentially susceptible to NK cell-
mediated killing. In this context, the expression of PD-1 on NK
cells may acquire a relevant role in NK-mediated anti-tumor
response against PDL-1/PDL-2+ tumors.15,16 The recent use of
anti-PD-1 or anti-PD-L1 monoclonal antibodies (mAbs) in
tumor therapy, resulted in strong improvements of the clinical
outcome particularly in melanoma and lung carcinoma
patients.17-19 In view of these important findings, it is crucial
to acquire information on the expression and on physiological
aspects of PD-1 in NK cells. In this study, we analyzed whether
PD-1 mRNA and PD-1 protein are detectable in the cytoplasm
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of resting NK cells of healthy individuals. We show that differ-
ent splicing isoforms of PD-1 mRNA are present in resting NK
cells in all the donors analyzed. In addition, we could consis-
tently detect a cytoplasmic pool of PD-1 protein. Both PD-1
mRNA and protein are present in higher amounts in mature
CD56dim, than in CD56bright, immature NK cells. Moreover,
PD-1 protein displays a diffuse cytoplasmic distribution and
a partial colocalization with Golgi compartments in all NK
cells. The presence of a PD-1 cytoplasmic pool is compatible
with a rapid surface expression of PD-1 in response to appro-
priate cellular stimuli.
Results and discussion
Considering both the important role of NK cells in anti-tumor
activity and the inhibitory effect exerted by PD-1 in PD-1+ NK
cells, we analyzed whether PD-1 expression was dependent on
a de novo synthesis or rather a preformed pool of PD-1 mRNA
existed in NK cells. In this context, previous studies showed that
PD-1 messenger RNA (mRNA) is present, in alternative splicing
isoforms, in unfractionated Peripheral BloodMononuclear Cells
(PBMC).20 However, no information was provided onwhich cell
type(s) express such mRNA. The human PD-1 coding sequence
was amplified by PCR using a pair of primers allowing the
identification of all the splicing isoforms (Figure 1(a)). Freshly
isolated PBMC were analyzed for PD-1 surface expression prior
to NK purification. A low PD-1 membrane expression, ranging
from 0.7% to 2.6% (Figure 1(b)), was observed on fresh PB
(“resting”) NK cells in the 14 donors analyzed. Two cell lines
NK92 and HEK-293T (hereafter HEK) were used as controls.
NK92 is an immortalized clonal cell line derived from a patient
with NK-cell lymphoma, which has recently been used in differ-
ent clinical trials.21 Since, according to the antibody datasheet,
HEK were indicated as a positive control, we included this cell
line as further control. As shown in Figure 1(c)the full length
(FL) form of PD-1 mRNA was the only detectable band in HEK
and NK92 cell lines. Analysis of resting NK cells revealed that,
although the FL form was the predominant band, other ampli-
fication products existed. These bands corresponded to the
following isoforms: Δexon3, Δexon2, Δexon2,3 and
Δexon2,3,4. Therefore, these data indicate that resting NK cells
contain a PD-1mRNA pool that consists not only of the FL form
but also of other splicing variants. On the basis of these results,
we further investigated whether also the PD-1 protein,
a transmembrane glycoprotein of approximately 50–55 kDa,22
was present in the NK cells. To this end, total protein extracts
obtained from resting NK cells of 14 different donors or from the
HEK and NK92 cell lines were analyzed. While NK92 cells
expressed a 55 kDa protein (upper band), HEK expressed
a lighter form of 37 kDa (lower band) (Figure 1(d)) possibly
representing the unglycosylated form of the protein.
Remarkably, in NK cells from HDs, both PD-1 bands (55 kDa
and 37 kDa) were present (Figure 1(d)). To further confirm that
the protein detected indeed corresponded to PD-1, we per-
formed experiments for silencing PD-1 expression. For this
purpose, NK cells were transfected with validated siRNA specific
for PD-1 or with mock siRNA. Reduction in PD-1 mRNA levels
was detected only in PD-1-specific siRNA-treated samples
(Figure 1(e)). In line with the mRNA data, a parallel reduction
in PD-1 protein was also documented (Figure 1(f–g)). Thus, our
data indicate that not only PD-1 mRNA but also PD-1 protein
are present in resting NK cells from HDs. We further investi-
gated the presence of PD-1 mRNA and protein in in vitro
activated NK cells or tumor associated NK cells isolated from
malignant pleural effusions (PE) (Figure 2(a–f)). NK cells, iso-
lated from three different HDs, were cultured with IL-2 for
3 weeks. As in resting NK cells, no significant PD-1 surface
expression could be detected in such IL-2 treated NK cells
(Figure 2(a)), while we could detect the presence of
a cytoplasmic pool of both PD-1 mRNA and protein (Figure 2
(b,c)). In particular, the RNA analysis for PD-1 isoforms
revealed the presence of the FL, Δexon3 and Δexon2,3 splicing
variants (Figure 2(b)). On the other hand, neither the Δexon2
nor the Δexon2,3,4 isoforms could be detected in the three
different donors analyzed. The PD-1 protein profile was similar
to the one detected in resting NK cells, as both the upper and
lower bands were present (Figure 2(c)). Of note, in all HDs
tested, the upper band appeared to be more expressed as com-
pared to the lower one. Analysis of PD-1 cytoplasmic pool in
pathological conditions was performed in NK cells isolated from
malignant PE in patients with primary or metastatic tumors
(four patients analyzed). Analysis of PD-1 isoforms allowed the
detection of all PD-1 splicing variants with the exception of
Δexon2,3 (Figure 2(d)). Assessment of PD-1 protein expression
revealed the presence of both lower and upper PD-1 bands
(Figure 2(e)) in resting and in vitro-activated NK cells.
However, in NK cells from PE, the lower band, possibly corre-
sponding to the unmodified protein, was more expressed than
the upper band. Thus, both PD-1 cytoplasmic mRNA and pro-
tein pool are also present in IL-2-activated NK cells and in
tumor-associated NK cells. Remarkably, in addition to PD-1
FL, the Δexon3 isoform was the only one present in all the
different NK cell populations analyzed. The Δexon3 isoform is
of particular interest because it codifies for a putative soluble
PD-1 (sPD-1) protein.20,23 Thus, we investigated whether, in
addition to sPD-1 transcript, also a soluble form of PD-1 was
released. For this purpose, supernatants collected from resting
and in vitro activated NK cells were analyzed by ELISA. The
same study was performed also on PE. As shown in Figure 2(f),
no sPD-1 was detected in supernatants of resting or IL-2-acti-
vated NK cells. These results are in line with previous studies in
which no sPD1 was detectable in healthy individuals.20 On the
other hand, sPD-1 was detected in PE (Figure 2(f)). These data
reveal that a soluble form of PD-1may indeed by released in
tumor environment, but they do not prove that it is NK-derived
as it may be produced by other cell types present in the pleural
cavity.
The majority of PB-NK cells are mature cytotoxic CD56dim
cells. Therefore, we further analyzed whether both mRNA and
protein expression was confined to this NK subset. To clarify this
point, we investigated whether also the immature CD56bright cells
would express PD-1 mRNA and protein. To this end, CD56dim
and CD56bright NK cells subsets were purified by cell sorting
(Figure S1) and analyzed separately for both PD-1 mRNA and
protein expression. Real-time amplification of the PD-1 coding
sequence and western blot analysis showed that also the less
mature CD56bright NK cells express both PD-1mRNA and protein
(Figure 3(a–c)). However, a comparative analysis revealed
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Figure 1. Detection of PD-1 mRNA isoforms and protein. (a) Schematic representation of PD-1 mRNA splicing variants. (b) Percentages of PD-1 surface expression
(ranging from 0,7% to 2,6%) in resting NK cells isolated from HDs. (c) Analysis of PD-1 mRNA isoforms on resting NK cells and on both the HEK and NK92 cell lines. NK
cells amplification profiles of two donors (HD1 and HD2), out of 14 analyzed, have been reported. (d) Total protein extracts from HEK, NK92 and resting NK cells were
analyzed for PD-1 expression. The figure reports the western blot profile of NK cells of four donors out of 14 analyzed. (e–g) PD-1 validation in NK cells transfected
with mock or PD-1 siRNA. Samples were collected 72 h after electroporation and analyzed for PD-1 mRNA and protein expression. (e) RT-PCR PD-1 mRNA expression,
in mock- (black column) and PD-1 siRNA- (gray column) transfected NK cells. PD-1 expression was normalized over Actin. Values are mean ± SEM. Statistical
significance has been determined by paired t-Test. (f) PD-1 protein expression in mock- and PD-1-siRNA transfected NK resting cells. A representative image from
three independent experiments has been reported. (g) PD-1 protein quantification of mock- (black columns) and PD-1-siRNA transfected (gray columns) NK cells. PD-
1 values, normalized over Actin, have been reported as a fold change calculated as a ratio between PD-1-siRNA and mock samples. Values, relative to three
independent experiments, are mean ± SEM. Statistical significance has been determined by paired t-Test.
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substantial differences in the two cell subsets. Indeed, CD56dim
display higher levels of both PD-1 transcript and protein as com-
pared to CD56bright cells. These data clearly indicate that the whole
population of PB-NK cells, also including CD56bright cells, contain
pools of both PD-1mRNA and protein. Remarkably, the CD56dim
subset, i.e. those cells that may express PD-1 at the cell surface,
display higher levels of PD-1. To further assess the type of PD-1
localization in the cytoplasm and to determine whether it was
expressed by all NK cells or only by a cell fraction, NK cells were
analyzed by immunofluorescence and confocal microscopy.
Figure 4(a) shows a diffuse distribution of cytoplasmic PD-1.
Notably, cytoplasmic PD-1 was detected in all resting NK cells
isolated from PB of different HDs. In a previous study on T cells,
PD-1 was found in the proximity of the Golgi compartments.24
Thus, we further investigated whether such localization also
occurred in NK cells. To this end, we used GM130 and TGN46
mAbs specific for the cis- and trans-Golgi cisternae, respectively.
Confocal microscopy analysis was performed both in resting NK
cells and in the NK92 and HEK cell lines. In order to detect
possible associations of endogenous PD-1 with the Golgi network,
wemeasured the distance between PD-1 dots close to the cisternae
and the Golgimarkers (GM130 and TGN46). Resting PB-NK cells
showed a substantial colocalization of PD-1 with both Golgi
compartments (Figure 4(b,c)). In contrast, in NK92 and HEK
cells, the mean distance between PD-1 and Golgi markers was
increased (Figures 4(b,c); S2(a,b)). Altogether, these data show that
PD-1 is homogeneously expressed in the cytoplasm of all resting
NK cells. In addition, it is detectable also in proximity of both the
cis- and trans-Golgi cisternae.
Our present data reveal that, despite the absent/low PD-1
surface expression, a cytoplasmic pool of PD-1 mRNA and pro-
tein exists in all resting NK cells. Similarly, PD-1 splicing variant
and protein were also detected in IL-2-activated NK cells and in
NK cells isolated from malignant PE from patients with primary
or metastatic pleural tumors. Different PD-1 mRNA splicing iso-
forms were detected in all the different NK cell populations
analyzed. Of particular interest, the splice variant lacking Exon3
encoding for a putative soluble form of PD-1. Different studies
have been performed on a possible role of sPD-1 as an antitumor
agent.23 Indeed in mice, delivery at the tumor site of plasmid
encoding sPD-1, resulted in increased antitumor immunity.25
Moreover, clinical studies in cancer patients have investigated
the presence of sPD-1 and its possible correlation with the overall
patients survival.26,27 Our data, in line with published data on
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Figure 2. Detection of PD-1 mRNA isoforms and protein in IL-2 activated NK cells and in NK cells isolated from malignant PE. (a) Percentages of PD-1 surface expression in
in vitro-activated NK cells isolated from HDs. (b) Analysis of PD-1 mRNA isoforms on NK cells. One representative HD, out of three analyzed, has been reported. (c) Total protein
extracts isolated from in vitro-activated NK cells were analyzed for PD-1 expression. (d) Analysis of PD-1 splicing variants in NK from PE. (e) PD-1 protein profile of PE infiltrating
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PBMC, demonstrate that sPD-1 is not released by resting or
in vitro-activated NK cells. Importantly, sPD-1 was detected in
malignant PE although its cell source remains to be elucidated.
Remarkably, both PD-1 transcript and protein were consistently
detectable in both CD56dim and CD56bright resting PB NK cell
subsets, although at higher levels in CD56dim NK cells. Of note,
intracytoplasmic flow cytometric analysis confirmed that in NK
cell populations lacking PD-1 surface expression the presence of
PD-1 could be detected in both CD56bright and CD56dim NK cells
subsets (data not shown). This is in line with data in T cells in
which, despite a strong reduction of PD-1 surface expression in
CD4+ cells after exposure to CD28SA, the intracytoplasmic stain-
ing revealed high levels of intracellular PD-1.28 In addition, as
shown also by confocal microscopy, all resting NK cells analyzed
contained a cytoplasmic pool of PD-1, detectable also in proximity
of the Golgi compartments. Since surface expression of PD-1
occurs primarily in certain pathological conditions (e.g. tumors/
viral infections), it was important to assess whether de novo
synthesis was required or rather a preformed cytoplasmic pool
was available. Our data revealed the presence of cytoplasmic PD-1
and are compatible with a possible prompt surface expression of
PD-1. In addition, the presence of PD-1 mRNA transcripts may
allow a rapid protein synthesis. In view of the regulatory role of
PD-1 in dampening over-reactive immune cell responses and in
maintaining peripheral tolerance, it is conceivable that its expres-
sion may be finely tuned by mechanisms ensuring its rapid
externalization. These mechanisms have been, in part, identified
in T lymphocytes but not in NK cells. It is possible that signaling
via NK receptor(s) and/or soluble and cellular factors produced in
pathological conditions may lead to PD-1 externalization. Indeed,
given the presence of PD-1 vesicles nearby the Golgi compart-
ments, it is conceivable that specific signals are required to pro-
mote fusion of PD-1 vesicles within the cytoplasm to the plasma
membrane. Preliminary studies in NK cells treated with different
cytokines (including IL2, IL15, IL18, IL1β, IL-17, TGF β) or
cocultured with some tumor cell lines did not result in PD-1
surface expression. Further studies, including epigenetic analyses,
which have been found to correlate with PD-1 expression espe-
cially in pathological conditions,29,30 are clearly required to unveil
the mechanisms involved in PD-1 surface expression in NK cells.
In conclusion, our study provides further insight into the
PD-1 expression in NK cells. Indeed, we show that even resting
NK cells are potentially capable of a prompt externalization of
PD-1. This notion, together with the possible synthesis of other
PD-1 isoforms, may be of relevance in view of the important
role of NK cells in killing tumor cells, particularly those that
have lost the surface expression of HLA-I molecules, thus
escaping cytolytic T lymphocytes-mediated control. Thus,
these data may offer clues for further investigations aimed at
unveiling the molecular mechanisms that regulate PD-1 protein
externalization in NK cells. These notions might allow the
design of new therapeutic approaches to improve NK cell-
mediated anti-tumor immune responses.
Materials and methods
Samples
This study included 14 buffy coats collected from volunteer
blood donors admitted to the blood transfusion center of
IRCCS Bambino Gesù Pediatric Hospital after obtaining
informed consent. The study was approved by the ethical
Committee of IRCCS Bambino Gesù Pediatric Hospital (825/
2014). The study on Pleural Effusion was approved by
Azienda Sanitaria Locale 3 (ASL, Genova, Italy) Ethics
Board (ID 33533184, 29/10/2013).
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Cell lines
Human embryonic kidney cells 293T (HEK 293T) were kindly
provided by Prof. M.C. Mingari and maintained in Dulbecco’s
Modified Eagle Medium (DMEM/F-12, with GlutaMAX)
(Gibco, Grand Island, NY) supplemented with 10% fetal bovine
serum (FBS) from Gibco, 1X Penicillin/streptomycin
(Euroclone, Pero, Italy) under 500 µg/ml Geneticin® Selective
Antibiotic (G418, Gibco) selection. HEK cell line was initially
used as a control for western blot analysis according to the anti-
body datasheet. NK92 cells were purchased from Leibniz
Institute DSMZ–German Collection of Microorganisms and
Cell Cultures (Braunschweig, Germany) and cultured in
Roswell Park Memorial Institute (RPMI) 1640 medium
(Euroclone), supplemented with 10% FBS (Gibco), 1%
Penicillin/streptomycin (Euroclone), 1% L-Glutamine
(Euroclone) and 5 ng/ml of Interleukin-2 (IL-2) (Novartis,
Basel, Switzerland).
Isolation of NK cells, flow cytometry analysis and cell
sorting
PBMC were obtained from buffy coats after density gradient
centrifugation over Ficoll Lympholyte®-H (Cederlane,
Burlington, Canada). Highly purified (≥98%) NK cells were sub-
sequently obtained by depletion of non-NK cells using Miltenyi
NK cell isolation kit (Miltenyi Biotech, Bergisch Gladbach,
Germany), according to the manufacturer’s instruction. To verify
the purity of NK cell separation, cells were stained with CD56-Pe-
Cy7 (BeckmanCoulter, Brea, CA,USA) andCD3-ECD (Beckman
Coulter) mAbs for 20 min at 4°C. NK cell samples were acquired
using the Cytoflex S (Beckman Coulter) flow cytometer and ana-
lyzed with the CytExpert 2.1 software (Beckman Coulter). PD-1
surface staining was performed incubating PBMCwith CD56-Pe-
Cy7, CD3-ECD, CD19-ECD (Beckman Coulter), CD14-ECD
(Beckman Coulter), PD-1 for 30 min at 4°C. The purified anti-
PD-1 mAb (PD1.3.1.3 clone, IgG2b) was originally isolated at the
Laboratoire Immunologie des Tumeurs, CRCM, Marseille-
Luminy (France). IgG2b-PE (Southern Biotech Birmingham,
USA) was used as a control. For cell sorting, isolated NK cells
were stained with CD56- Pe-Cy7 and CD3-ECD. CD56dim and
CD56bright cells were sorted to a purity of ≥98% with the MoFlo
Astrios sorter (Beckman Coulter) using the Summit software
(Beckman Coulter). The purity of cells separation was controlled
by flow cytometry using CD56- Pe-Cy7 and CD3-ECD. After
sorting, NK cells were centrifuged at 211 g, for 5 min at 4°C.
Pleural Effusion (PE) cells were obtained by centrifugation at
400 g for 10 min. Isolation of NK cells from PE was performed
using theMiltenyi NK cell isolation kit (Miltenyi Biotech), accord-
ing to the manufacturer’s instruction. For protein isolation, NK
cell pelletswere stored at –80°C; forRNA isolation, cell pelletswere
resuspended in Trizol (Ambion, Invitrogen Corporation, Applera
Norwalk, USA) and then stored at –80°C.
In vitro NK cells activation
To obtain polyclonal activated NK cells, highly purified NK cells
obtained from HDs, were cultured with NK macs basal medium
(Miltenyi Biotech) supplemented with the NKMacs supplement,
10% FBS (Gibco), 1% L-glutamine (Euroclone), 1% Penicillin/
streptomycin (Euroclone), and 600 U/ml of IL-2 (Novartis).
Every 3–4 days NK cells were expanded until the right exponen-
tial growth phase was reached to perform experiments.
RNA extraction
NK cells pellets were resuspended in Trizol (Ambion). After
addition of Chloroform (Sigma-Aldrich, St. Louis, USA) sam-
ples were centrifuged at 12,000 g for 15 min at 4°C. The
aqueous phase was removed and RNA was then isolated with
the Qiagen RNeasy Universal kit (Qiagen, Hilden, Germany)
according to manufacturer’s instruction. HEK and NK92 cell
pellets were resuspended in Trizol (Applied) and RNA was
isolated according to manufacturer’s instruction. After extrac-
tion, purity of mRNA was determined by A260/A280 (between
1.2 and 2.2) and A260/A230 (1.7). mRNA samples were then
treated with DNase I Amplification Grade (Invitrogen,
Carlsbad, CA, USA) to eliminate any genomic DNA contam-
ination. cDNAs were synthetized by oligo dT using the
Superspcrit® IV First-Strand Synthesis System (Invitrogen)
according to the manufacturer’s instruction.
PCR for PD-1 isoforms
To detect PD-1 mRNA transcripts isoforms, cDNAs were
amplified using the EmeralAMP® GT PCR Master Mix
(Takara Bio Inc., Kusatsu, Japan). Amplification was carried
out with the ProFlex PCR system (Applied Biosystems, Foster
City, CA, USA) using the following cycling profile: an initial
hold at 95°C for 30 sec, 40 cycles of 94°C for 1 min, 64°C for
1 min and 72°C for 1 min; final extension step of 72°C for
10 min. The following primers were used for the amplifica-
tion: PD-1 all F: 5’-GCGGCCAGGATGGTTCTTA-3’; PD-1
all R 5’-TACTCCGTCTGCTCAGGGA-3’. PCR products were
separated by electrophoresis on a 2% agarose gel. Images were
collected using the Uvitec Mini HD9 transilluminator system
(Uvitec Ltd. Cambridge).
Real-time PCR
cDNAs from NK cells were synthetized as described above.
Quantitative Real-time PCR was performed with the
QuantStudio 6 Flex PCR (Applied Biosystems) using the
PowerUp SYBR Green Master mix (Applied Biosystems) accord-
ing to manufacturer’s instruction. Relative quantification of
mRNA was determined by the ΔΔCt method. PD-1 mRNA
expression was normalized against ActinB expression. Primers
for real time are as follows: PD-1-F 5’-CAGGG
TGACAGAGAGAAGGG-3’; PD-1-R 5’-CCTGGCTCCTA
TTGTCCCTC-3’; ActB-F 5’-ACCGCGAGAAGATGACCCAGA
-3’; ActB-R 5’-GGATAGCACAGCCTGGATAGCAA-3’
Protein extract and western blot analysis
NK, NK92 and HEK cells pellets were resuspended in RIPA
buffer with 1X Halt Protease and phosphatase inhibitor cock-
tail (Thermo Fisher Scientific, Waltham, Massachusetts, USA)
and incubated on ice for 20 min. After centrifugation for
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15 min at 21.130 g at 4°C, supernatants were recovered.
Protein concentration was measured with the BCA assay
(Perkin Elmer, Waltham, Massachusetts, USA) according to
manufacturer’s instruction. Protein extracts were fractionated
by SDS-page gel electrophoresis and transferred to a PVDF
membrane (Ge Healthcare, Little Chalfont, UK). After incu-
bation in TBST with 5% nonfat dry milk (Cell Signaling
Technology, Danvers, Massachusetts, USA) with gentle agita-
tion for 60 min, the membrane was incubated with α-PD-1
1:1000 (Abnova, Taipei, Taiwan) (this mAb was selected
based on its good capacity of staining the PD-1 intracytoplas-
mic form, tested in HEK cell line) or with α-β-Actin 1:10000
(Sigma-Aldrich). After washes, membrane was incubated with
the secondary antibody: goat-α-mouse-HRP (Santa Cruz,
Dallas, Texas, USA). Signals were developed with the ECL
prime system (Ge Healthcare) according to manufacturer’s
instruction and detected with the Uvitec Mini HD9 technol-
ogy (Uvitec Ltd, Rugby, UK). Bands quantification was per-
formed using the Ninealliance© software (Uvitec).
siRNA transfection
NK cells were transfected with Silencer® Negative Control siRNA
(mock) (Thermo Fisher Scientific) or with the Silencer® PDCD1
siRNA (Assay ID 5525, Thermo Fisher Scientific) using the Neon
electroporation system (Invitrogen), according to manufacturer’s
instruction. After transfection NK cells were cultured in RPMI
(Euroclone) 10% FBS (Gibco), 1% Penicillin/streptomycin
(Euroclone), 1% L-Glutamine (Euroclone) and 600 U/ml of IL-2
(Novartis). NK cells were collected 72 hrs post-transfection, by
centrifugation at 211 g at 4°C for 5 min. For subsequent protein
isolation, NK cell pellets were immediately stored at −80°C. For
RNA isolation, pellets were resuspended in Trizol (Ambion) prior
storage at −80°C. Protein and RNA isolations were performed as
described above.
sPD-1 ELISA
Soluble PD-1 (sPD-1) release was measured by enzyme-linked
immunosorbent assay (ELISA) using the human PD-1 antibody
duosets ELISA development kit DY1086 (R&D Systems, Inc.
Minneapolis, USA) and the DuoSet ELISA Ancillary Reagent kit
2 DY008 (R&D). Plates were coated overnight with capture anti-
body (2 ug/ml). The following day, after washes (3 × 300 ul with
Wash Buffer 1X) 100 ul of Reagent Diluent (5% BSA final con-
centration) were added to each well and plate was incubated for
1 hr at 700 rpm. After a washing step as before, 100 ul of sample or
standards were added, plate was sealed and incubated for 2 hrs
with gentle shaking. Calibration curve consisted of 1:2 dilutions of
the standard material ranging from 2,5 ng/ml to 0,0097 ng/ml.
The plate was subsequently washed and incubated with 100 ul of
Detection Antibody (200 ng/ml) for 2 hrs with gentle shaking.
After repeating the washing step, 100 ul of Streptavidin-HRP was
added to each well. The plate was incubated in the dark for
40 min, washed and then treated with 100 ul of Substrate
Solution for 20 min. After addition of 50 ul of Stop Solution,
optical density was immediately measured using the Synergy H1
Reader (Biotek, Winooski, USA). Sample was read at 450 nm and
540 nmwavelengths and to correct optical imperfection reading at
540 nm was subtracted to reading at 450 nm. sPD-1 concentra-
tions (pg/ml) were calculated using the four-point-fit calibration
curve of standard dilutions.
Confocal microscopy
Freshly isolated purified blood NK cells were adhered to
microscope slides (BD, Franklin Lakes, New Jersey, USA),
previously coated with poly-L-lysine (Sigma) for 30 min at
room temperature. Cells were fixed with cold
Paraformaldehyde 4% (Sigma) for 5 min and then permea-
bilized with 0.1% Triton X-100 (Sigma Aldrich) for 8 min.
After washes with PBS cells were blocked with PBS-BSA3%
for 30 min. Cells were then incubated with α-PD-1 1:400
(Abnova) overnight at 4°C. After washes cells were incu-
bated with Alexa Fluor 488 goat-α-mouse 1:800 (Molecular
Probe, Eugene, Oregon, USA) for 1 hr at room temperature
(RT). Cells were washed in PBS and then incubated with α-
GM130 1:200 (Abcam, Cambridge, UK) or α-TGN46 1:200
(Abcam) for 1 hr at RT. Cells were then washed and sub-
sequently incubated with Alexa Fluor 546 goat-α-rabbit
1:400 (Molecular Probe) 1 hr at RT. After washes, cells
were mounted with Vectashield® Antifade mounting med-
ium containing 1,5 µg/ml of DAPI (Vectorlab, Burlingame,
CA, USA). Samples were stored at 4°C. Confocal micro-
scopy was performed on a Leica TCS-SP8X laser-scanning
confocal microscope (Leica Microsystems, Mannheim,
Germany) equipped with tunable white light laser (WLL)
source, 405 nm diode laser, 3 Internal Spectral Detector
Channels (PMT) and 2 Internal Spectral Detector
Channels (HyD) GaAsP. Sequential confocal images were
acquired using an HCPLAPO 63x oil-immersion objective
(1.40 numerical aperture, NA, Leica Microsystems) with
a 1024 × 1024 format, scan speed 400 Hz, and z-step size
of 0.3 µm. Z-reconstructions were imported into LAS X 3D
software (Leica Microsystems) to obtain their 3D surface
rendering. Acquisition settings (i.e. lasers’ power, beam
splitters, filter settings, pinhole diameters and scan mode)
were the same for all examined samples of each staining.
The distances between PD-1 spots, closer to the Golgi net-
work, and Golgi cisternae, were manually measured in the
focal central plane of the Golgi compartment, using LAS
X analysis software (Leica Microsystems) in five digital
images randomly selected and acquired for each cell sample.
Tables of images are processed using Adobe Photoshop CS4
software (Adobe Systems Inc).
Statistical analysis
Statistical analyses were performed using the GraphPad Prism
6.0 (La Jolla, CA, USA) software. Values were expressed as
mean ± SEM. P values less than 0.05 were considered statis-
tically significant. * P˂ 0.05, ** P˂ 0.01 *** P˂ 0.001.
Abbreviations
mRNA messanger RNA
PD-1 Programmed Cell Death protein 1
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